These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1408 related articles for article (PubMed ID: 10928178)
1. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178 [TBL] [Abstract][Full Text] [Related]
2. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442 [TBL] [Abstract][Full Text] [Related]
3. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668 [TBL] [Abstract][Full Text] [Related]
4. MIA, a novel serum marker for progression of malignant melanoma. Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451 [TBL] [Abstract][Full Text] [Related]
7. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031 [TBL] [Abstract][Full Text] [Related]
8. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664 [TBL] [Abstract][Full Text] [Related]
9. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers]. Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520 [No Abstract] [Full Text] [Related]
10. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744 [TBL] [Abstract][Full Text] [Related]
11. Results of the determination of serum markers in patients with malignant melanoma. Lugović L; Situm M; Buljan M; Poduje S; Sebetić K Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741 [TBL] [Abstract][Full Text] [Related]
12. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531 [TBL] [Abstract][Full Text] [Related]
15. [Serum levels of S-100b protein after four years follow-up of patients with melanoma]. Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167 [TBL] [Abstract][Full Text] [Related]
16. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538 [TBL] [Abstract][Full Text] [Related]
17. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333 [TBL] [Abstract][Full Text] [Related]
18. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205 [TBL] [Abstract][Full Text] [Related]
19. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]